Results of breeding neonatally transplanted mucopolysaccharidosis VII adults as compared to mice receiving β-glucuronidase enzyme
| Treatment of breeding pairs . | Number of matings . | Mean number born (± SD) . | Mean number weaned (± SD) . | % Survival . |
|---|---|---|---|---|
| Normal | 40 | 6.3 ± 2.2 | 5.9 ± 2.2 | 93.7% |
| 6xERT | 8 | 7.0 ± 2.0 | 5.6 ± 1.5 | 80.0% |
| 3xBMT | 9 | 6.7 ± 2.5 | 5.8 ± 2.8 | 86.6% |
| Treatment of breeding pairs . | Number of matings . | Mean number born (± SD) . | Mean number weaned (± SD) . | % Survival . |
|---|---|---|---|---|
| Normal | 40 | 6.3 ± 2.2 | 5.9 ± 2.2 | 93.7% |
| 6xERT | 8 | 7.0 ± 2.0 | 5.6 ± 1.5 | 80.0% |
| 3xBMT | 9 | 6.7 ± 2.5 | 5.8 ± 2.8 | 86.6% |
Male and female MPS VII neonates were treated with either 6 weekly injections of recombinant murine GUS enzyme replacement therapy (6xERT) or 3 daily injections of +/+ syngeneic bone marrow without myeloablation (3xBMT).
ERT indicates enzyme replacement therapy; for other abbreviations see Tables 1 and 2.